AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11387182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse recall group vs GP recall group
Number of subjects: 1906
Study 9591860 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine antiseptic
Number of subjects: 30
Study 9591860 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridex oral rinse
Number of subjects: 30
Study 9591860 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 30
Study 7820960 — intervention group
Group type: COMPARATOR
Intervention: CDP-choline (cytidine diphosphate choline) administered daily for one week after a single intravenous injection.
Number of subjects: 10
Study 2971550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 2 HCl
Number of subjects: 36
Study 2971550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 2971550 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 36
Study 31470769 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Strategies (yes)
Number of subjects: 102
Study 31470769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapersonal Strategies (yes)
Number of subjects: 102
Study 31470769 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Strategies (no)
Number of subjects: 102
Study 31470769 — intervention group
Group type: COMPARATOR
Intervention: Intrapersonal Strategies (no)
Number of subjects: 102
Study 29459064 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐CRM197
Number of subjects: 0
Study 29459064 — intervention group
Group type: COMPARATOR
Intervention: PRP‐T
Number of subjects: 0
Study 27638357 — intervention group
Group type: COMPARATOR
Intervention: trivalent attenuated OPV (tOPV) at 6, 10, and 14 weeks
Number of subjects: 210
Study 27638357 — intervention group
Group type: COMPARATOR
Intervention: bivalent OPV (bOPV) at 6, 10, and 14 weeks
Number of subjects: 210
Study 27638357 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV at 6, 10, and 14 weeks plus IPV at 14 weeks
Number of subjects: 210
Study 24499168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg + metformin
Number of subjects: 180
Study 24499168 — intervention group
Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 180
Study 22310314 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer and stronger hyperpolarizing currents
Number of subjects: 10
Study 22310314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical model of human sensory axons
Number of subjects: 10
Study 22310314 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulation of voltage dependence of I(h)
Number of subjects: 10
Study 22310314 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling of I(h) isoforms
Number of subjects: 10
Study 22310314 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling of sensory axons
Number of subjects: 10
Study 21211455 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy plus sapheno-femoral junction (SFJ) ligation
Number of subjects: 60
Study 21211455 — intervention group
Group type: COMPARATOR
Intervention: Standard stripping surgery
Number of subjects: 60
Study 18496564 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (subcutaneous treatment for 12 weeks)
Number of subjects: 12
Study 15902172 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent dehydrated cadaveric fascia lata patch
Number of subjects: 162
Study 15902172 — intervention group
Group type: COMPARATOR
Intervention: No patch (control group)
Number of subjects: 162
Study 15902172 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant transvaginal Cooper's ligament sling procedures
Number of subjects: 162
Study 12735677 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg fenoterol
Number of subjects: 23
Study 12735677 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg oxitropium bromide
Number of subjects: 23
Study 12735677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10710765 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 acquisition trials
Number of subjects: 50
Study 10710765 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 acquisition trials
Number of subjects: 50
Study 10710765 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 acquisition trials
Number of subjects: 50
Study 10710765 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 acquisition trials
Number of subjects: 50
Study 10710765 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 acquisition trials
Number of subjects: 50
Study 7729740 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackson‐Pratt closed‐suction drainage (Group 1, patients 1‐60)
Number of subjects: 120
Study 7729740 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Group 2, patients 61‐120)
Number of subjects: 120
Study 1823383 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 5-, 10-, and 20-mg treatment groups
Number of subjects: 34
Study 1823383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7192338 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 16
Study 7192338 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 16
Study 7192338 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 16
Study 31765343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance training (traditional strength training + plyometrics)
Number of subjects: 59
Study 31765343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance training with weightlifting
Number of subjects: 59
Study 27993496 — intervention group
Group type: COMPARATOR
Intervention: Standard cementless femoral stem
Number of subjects: 60
Study 27993496 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter cementless femoral stem (35-mm shorter)
Number of subjects: 60
Study 27639753 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 300 mg Q4W
Number of subjects: 0
Study 27639753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23490032 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA (tissue plasminogen activator)
Number of subjects: 0
Study 23490032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24223344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine 0.5mg/kg
Number of subjects: 75
Study 24223344 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) ketamine 0.5 mg/kg
Number of subjects: 75
Study 24223344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 20697700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 300 mg b.i.d. for 4 days
Number of subjects: 12
Study 20697700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 400/100 mg b.i.d. for 4 days
Number of subjects: 12
Study 20697700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18441036 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-mediated therapy
Number of subjects: 20
Study 18441036 — intervention group
Group type: COMPARATOR
Intervention: Sling suspension phase
Number of subjects: 20
Study 16159624 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 24
Study 16159624 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 12673669 — intervention group
Group type: EXPERIMENTAL
Intervention: Testim (1% testosterone topical gel, 50 mg)
Number of subjects: 29
Study 12673669 — intervention group
Group type: COMPARATOR
Intervention: AndroGel (1% testosterone topical gel, 50 mg)
Number of subjects: 29
Study 10554519 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8907096 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic relationship quality reported by patients early in treatment
Number of subjects: 0
Study 8907096 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic relationship quality
Number of subjects: 0
Study 8907096 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic treatments (3 brief treatments for depression)
Number of subjects: 0
Study 8443666 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel (group 1)
Number of subjects: 101
Study 8443666 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery (group 2)
Number of subjects: 101
Study 3080050 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dexamethasone (480 mg over 12 days)
Number of subjects: 113
Study 3080050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 31668575 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking Block Modified Krackow (LBMK) technique
Number of subjects: 20
Study 31668575 — intervention group
Group type: COMPARATOR
Intervention: Giftbox technique
Number of subjects: 20
Study 30002304 — intervention group
Group type: EXPERIMENTAL
Intervention: MICE (20 min, 70% of maximal heart rate)
Number of subjects: 12
Study 30002304 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE (10 × 1 min at 90% of maximal heart rate with 1 min recovery)
Number of subjects: 12
Study 30002304 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE
Number of subjects: 12
Study 30002304 — intervention group
Group type: COMPARATOR
Intervention: CON (no exercise)
Number of subjects: 12
Study 27682852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) 0.25 mg
Number of subjects: 45
Study 27682852 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) 0.625 mg
Number of subjects: 45
Study 25027493 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum auricular acupuncture plus standard obstetric care (VAAc)
Number of subjects: 212
Study 25027493 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific auricular acupuncture plus standard obstetric care (NSAAc)
Number of subjects: 212
Study 25027493 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific placebo auricular acupuncture plus standard obstetric care (PAAc)
Number of subjects: 212
Study 25027493 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care (SOC)
Number of subjects: 212
Study 25027493 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (VAAc, NSAAc, PAAc)
Number of subjects: 212
Study 25156847 — intervention group
Group type: COMPARATOR
Intervention: General Practitioners (GPs)
Number of subjects: 5563
Study 25156847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologists
Number of subjects: 5563
Study 25156847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GPs and Cardiologists
Number of subjects: 5563
Study 21787210 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 100
Study 21787210 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream
Number of subjects: 100
Study 21787210 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (placebo)
Number of subjects: 100
Study 19541679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 microg kg(‐1) in normal saline 1 ml
Number of subjects: 60
Study 17478142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 12 mg intravenously before PCI
Number of subjects: 368
Study 17478142 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously before PCI
Number of subjects: 368
Study 15926604 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 selective inhibitors
Number of subjects: 0
Study 12169832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG supplementation (6 x 10(9) cfu once a day until discharge)
Number of subjects: 585
Study 9501784 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pushing (commencement of pushing within one hour of the diagnosis of full dilatation)
Number of subjects: 135
Study 9501784 — intervention group
Group type: COMPARATOR
Intervention: Delayed pushing (delaying pushing for a maximum of three hours from the time of diagnosis of full dilatation)
Number of subjects: 135
Study 8700659 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week stress management training program
Number of subjects: 45
Study 8700659 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 45
Study 1909541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20‐40 mg day‐1)
Number of subjects: 16
Study 1909541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6357035 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 72
Study 6357035 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 72
Study 6357035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both inpatient and outpatient treatment
Number of subjects: 72
Study 30924894 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive prenatal testing (NIPT) with almost certain but limited information
Number of subjects: 2436
Study 30924894 — intervention group
Group type: COMPARATOR
Intervention: Invasive testing (IT) with complete karyotyping
Number of subjects: 2436
Study 30924894 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes driven by risk aversion
Number of subjects: 2436
Study 30924894 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes driven by ambiguity aversion
Number of subjects: 2436
Study 30924894 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes involving both risk and ambiguity aversion
Number of subjects: 2436
Study 29208884 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (100μgm) orally 60 minutes before induction of anaesthesia
Number of subjects: 60
Study 29208884 — intervention group
Group type: COMPARATOR
Intervention: No premedication (Group A)
Number of subjects: 60
Study 27444313 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose lafutidine 10 mg under fasting conditions
Number of subjects: 12
Study 27444313 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose lafutidine 10 mg twice daily over 6 days
Number of subjects: 12
Study 27444313 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose lafutidine 10 mg under fed conditions
Number of subjects: 12
Study 27444313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine 10-40 mg
Number of subjects: 12
Study 25111186 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol
Number of subjects: 0
Study 25111186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 22055006 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection PVB (20 mL 0.5% bupivacaine with 1:200,000 epinephrine at T6, n = 25)
Number of subjects: 50
Study 22055006 — intervention group
Group type: COMPARATOR
Intervention: Multiple-injection PVB (5 injections of 4 mL each at T4 to T8, n = 25)
Number of subjects: 50
Study 19601490 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gum 1 (TG1) containing sucrose
Number of subjects: 14
Study 19601490 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gum 2 (TG2) containing xylitol and zinc citrate
Number of subjects: 14
Study 19601490 — intervention group
Group type: COMPARATOR
Intervention: Cysteine 6 mM rinse followed by chewing test gums
Number of subjects: 14
Study 17894652 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 440
Study 17894652 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 440
Study 17894652 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 440
Study 15091194 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (1000 mg/day for 3 months)
Number of subjects: 46
Study 15091194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12243810 — intervention group
Group type: COMPARATOR
Intervention: q.d. RT (60 Gy in 30 daily fractions) with etoposide and cisplatin (EP)
Number of subjects: 234
Study 12243810 — intervention group
Group type: EXPERIMENTAL
Intervention: b.i.d. RT (30 Gy in 20 fractions b.i.d. followed by a 2-week break and then 30 Gy in 20 fractions b.i.d.) with etoposide and cisplatin (EP)
Number of subjects: 234
Study 9828758 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g fructose/kg body weight
Number of subjects: 12
Study 9828758 — intervention group
Group type: COMPARATOR
Intervention: 0.75 g starch/kg body weight
Number of subjects: 12
Study 7926574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical gel containing 0.5 mg PgE2
Number of subjects: 0
Study 7926574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal tablet containing 3 mg PgE2
Number of subjects: 0
Study 7926574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both gel and tablet
Number of subjects: 0
Study 7926574 — intervention group
Group type: COMPARATOR
Intervention: Intracervical gel
Number of subjects: 0
Study 7926574 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-sympathicomimetics
Number of subjects: 0
Study 7926574 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin induction
Number of subjects: 0
Study 1987242 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Number of subjects: 79
Study 1987242 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography
Number of subjects: 79
Study 7200716 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol intoxication
Number of subjects: 64
Study 7200716 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption guised as tonic
Number of subjects: 64
Study 7200716 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy
Number of subjects: 64
Study 7200716 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intoxication
Number of subjects: 64
Study 30774321 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 300
Study 30774321 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 300
Study 29889843 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin group
Number of subjects: 228
Study 29889843 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline group
Number of subjects: 228
Study 27017282 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 150 µg/body/day
Number of subjects: 49
Study 27017282 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 300 µg/body/day
Number of subjects: 49
Study 27017282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 25693332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg . kg‐1
Number of subjects: 98
Study 25693332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 25693332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 98
Study 21075537 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 20
Study 21075537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 20
Study 21075537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Gabapentin and Cetirizine
Number of subjects: 20
Study 19204524 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 154
Study 19204524 — intervention group
Group type: EXPERIMENTAL
Intervention: Illicit drug use
Number of subjects: 154
Study 19204524 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem drug use
Number of subjects: 154
Study 19204524 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional treatment for substance use
Number of subjects: 154
Study 17963050 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG)
Number of subjects: 106
Study 17963050 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 106
Study 15000887 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.1 mg/kg/min) intravenously for anesthesia maintenance
Number of subjects: 30
Study 15000887 — intervention group
Group type: COMPARATOR
Intervention: Control group received fentanyl 10 microg/kg intravenously and inhaled enflurane (1 %‐1.5 %)
Number of subjects: 30
Study 12471945 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptotically correct method for sample size calculation
Number of subjects: 0
Study 12471945 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate method for sample size calculation
Number of subjects: 0
Study 12471945 — intervention group
Group type: COMPARATOR
Intervention: Existing method based on crude approximation
Number of subjects: 0
Study 9436017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus vaccination before repeat skin testing
Number of subjects: 77
Study 9436017 — intervention group
Group type: COMPARATOR
Intervention: No tetanus vaccination before repeat skin testing
Number of subjects: 77
Study 9436017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid
Number of subjects: 77
Study 9436017 — intervention group
Group type: EXPERIMENTAL
Intervention: Mumps skin test antigen
Number of subjects: 77
Study 9436017 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida skin test antigen
Number of subjects: 77
Study 8083096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 Gy/hr
Number of subjects: 204
Study 8083096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 Gy/hr
Number of subjects: 204
Study 2522405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low initial dosage of acitretin (10, 30, 50 mg/day)
Number of subjects: 66
Study 2522405 — intervention group
Group type: COMPARATOR
Intervention: Constant dosage of acitretin (30 mg/day)
Number of subjects: 66
Study 2522405 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial dosage of acitretin (50, 30, 10 mg/day)
Number of subjects: 66
Study 2522405 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (10, 30, or 50 mg/day) during open phase
Number of subjects: 66
Study 30910964 — intervention group
Group type: EXPERIMENTAL
Intervention: Debt relief worth up to Singapore dollars 5,000 (∼3 month's household income)
Number of subjects: 196
Study 30910964 — intervention group
Group type: EXPERIMENTAL
Intervention: Debt relief worth ∼1 month's household income
Number of subjects: 196
Study 30910964 — intervention group
Group type: EXPERIMENTAL
Intervention: Debt relief magnitude
Number of subjects: 196
Study 28706106 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrievable inferior vena cava (IVC) filter
Number of subjects: 240